Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 30 of 1,261
  1. US 12357702

    Peptidic diagnostic compositions

    S. M. DISCOVERY GROUP INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  2. US 12357617

    Discovery of novel anti-infectives for gram negative pathogens

    The Regents of the University of California · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  3. US 12357659

    Production of megakaryocytes or platelets from monocytes

    The Board of Regents of the University of Texas System · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  4. US 12357640

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  5. US 12357697

    Pharmaceutical compositions comprising bupropion and cysteine

    AXSOME THERAPEUTICS, INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  6. US 12357599

    Prodrugs of treprostinil

    United Therapeutics Corporation · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  7. WO 2025146444

    DAROLUTAMIDE EN COMBINAISON AVEC DES INHIBITEURS DE BRAF ET DE MEK POUR LE TRAITEMENT D'UN MÉLANOME

    BAYER AG [DE] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  8. WO 2025147499

    LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE

    ABBVIE INC [US] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  9. WO 2025146482

    FINÉRÉNONE DESTINÉE À ÊTRE UTILISÉE DANS UN PROCÉDÉ DE PRÉVENTION OU DE TRAITEMENT D'UNE INSUFFISANCE CARDIAQUE CHEZ UN PATIENT RECEVANT UN INHIBITEUR DE CYP3A4 OU UN INDUCTEUR DE CYP3A4

    BAYER AG [DE] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  10. US 2025222125

    Anti-FGFR2b Antibodies, Conjugates and Methods of Use

    BEIGENE LTD [KY] · Granted Jul 10, 2025 · Expires Jul 5, 2045

    granted
  11. US 12350313

    Activin receptor type IIa variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  12. US 12351581

    Compounds for FGFR inhibition

    Cogent Biosciences, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  13. US 12351653

    Pharmaceutical compositions comprising novel cyclic peptides

    LISATA THERAPEUTICS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  14. US 12351611

    Molecules for organelle-specific protein delivery

    Larimar Therapeutics, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  15. US 12350262

    Methods of treatment for cystic fibrosis

    Vertex Pharmaceuticals Incorporated · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  16. US 12350399

    Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

    The Regents of the University of California · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  17. US 12350270

    Antimalarial agents

    MSD R&D (China) Co. Ltd. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  18. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  19. US 12350245

    Stable oral suspensions of baclofen

    ANI Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  20. US 12350242

    Binge behavior regulators

    CLEARMIND MEDICINE INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  21. US 12350250

    Aggrelytes for treating ocular conditions

    The Regents of the University of Colorado, a Body Corporate · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  22. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  23. US 12350285

    Compounds and methods for reducing ATXN3 expression

    Ionis Pharmaceuticals, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  24. US 12350274

    Nucleotide analogs

    United States Government as represented by the Department of Veterans Affairs · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.